Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.4K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.8K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.8K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.7K
Lymphatic Vessels and Lymph Transport01:16

Lymphatic Vessels and Lymph Transport

24.6K
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
24.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.

Cancer investigation·2026
Same author

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Research square·2026
Same author

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

American journal of clinical oncology·2025
Same author

Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma.

Frontiers in oncology·2025
Same author

Harnessing genomic profiling for improved urothelial cancer outcomes.

Expert review of anticancer therapy·2025
Same author

Bruton Tyrosine Kinase Degraders: Current Concepts.

American journal of clinical oncology·2025

Related Experiment Video

Updated: Apr 3, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K

Chronic Lymphocytic Leukemia: Current Concepts.

Eun-Mi Yu1, Adam Kittai2, Imad A Tabbara3

  • 1Department of Hematology/ Oncology, George Washington University, Washington, DC, U.S.A.

Anticancer Research
|September 27, 2015
PubMed
Summary

Chronic lymphocytic leukemia (CLL) requires careful treatment balancing quality of life and disease control, especially in elderly patients. Advances in genetic profiling enable tailored therapies for different CLL patient subgroups.

Keywords:
Chronic lymphocytic leukemiaibrutinibidelalisibofatumumabreviewrituximabsmall-cell lymphoma

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K

Related Experiment Videos

Last Updated: Apr 3, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults.
  • While early-stage CLL may not require immediate treatment, advanced stages significantly impact quality of life and survival.
  • Treatment decisions for CLL are complex due to the disease's prevalence in the elderly, necessitating a balance between preserving functional status and controlling the leukemia.

Purpose of the Study:

  • To review current standard therapies for chronic lymphocytic leukemia (CLL) across different patient subgroups.
  • To discuss treatment strategies in both front-line and relapsed/refractory settings.
  • To provide an overview of novel therapeutic agents demonstrating efficacy in CLL.

Main Methods:

  • Review of current standard therapies based on patient age and functional status.
  • Analysis of treatment approaches for front-line and relapsed/refractory CLL.
  • Concise review of emerging novel agents for CLL treatment.

Main Results:

  • Molecular and genetic profiling allows for the identification of CLL patient subgroups.
  • Tailored therapies can be selected based on these identified subgroups.
  • Novel agents show considerable efficacy in managing CLL.

Conclusions:

  • Personalized treatment strategies are emerging for chronic lymphocytic leukemia (CLL) based on molecular and genetic profiles.
  • Balancing functional status with disease control remains a key consideration in elderly CLL patients.
  • Novel agents represent a promising frontier in CLL management.